Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Akebia Therapeutics (AKBA) Liabilities and Shareholders Equity (2016 - 2025)

Historic Liabilities and Shareholders Equity for Akebia Therapeutics (AKBA) over the last 10 years, with Q3 2025 value amounting to $364.2 million.

  • Akebia Therapeutics' Liabilities and Shareholders Equity rose 7579.82% to $364.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.2 billion, marking a year-over-year increase of 3868.94%. This contributed to the annual value of $220.7 million for FY2024, which is 870.2% down from last year.
  • According to the latest figures from Q3 2025, Akebia Therapeutics' Liabilities and Shareholders Equity is $364.2 million, which was up 7579.82% from $345.6 million recorded in Q2 2025.
  • Over the past 5 years, Akebia Therapeutics' Liabilities and Shareholders Equity peaked at $628.7 million during Q1 2021, and registered a low of $207.1 million during Q3 2024.
  • Its 5-year average for Liabilities and Shareholders Equity is $376.3 million, with a median of $345.6 million in 2025.
  • Its Liabilities and Shareholders Equity has fluctuated over the past 5 years, first tumbled by 5211.92% in 2023, then surged by 7579.82% in 2025.
  • Akebia Therapeutics' Liabilities and Shareholders Equity (Quarter) stood at $529.3 million in 2021, then plummeted by 32.74% to $356.1 million in 2022, then plummeted by 32.12% to $241.7 million in 2023, then fell by 8.7% to $220.7 million in 2024, then surged by 65.02% to $364.2 million in 2025.
  • Its last three reported values are $364.2 million in Q3 2025, $345.6 million for Q2 2025, and $310.2 million during Q1 2025.